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DOI 10.1016/j.ccr.2010.10.024SUMMARYCancer cells neutralize p53 by deletion, mutation, proteasomal degradation, or sequestration to achieve
a pathologic survival advantage. Targeting the E3 ubiquitin ligase HDM2 can lead to a therapeutic surge in
p53 levels. However, the efficacy of HDM2 inhibition can be compromised by overexpression of HDMX, an
HDM2 homolog that binds and sequesters p53. Here, we report that a stapled p53 helix preferentially targets
HDMX, blocks the formation of inhibitory p53-HDMX complexes, induces p53-dependent transcriptional
upregulation, and thereby overcomes HDMX-mediated cancer resistance in vitro and in vivo. Importantly,
our analysis of p53 interaction dynamics provides a blueprint for reactivating the p53 pathway in cancer
by matching HDM2, HDMX, or dual inhibitors to the appropriate cellular context.INTRODUCTION
p53 plays an essential regulatory role in the development and
homeostasis of cells and tissues (Vousden and Lane, 2007). As
‘‘guardian of the genome,’’ p53 prevents the emergence of
genetically variant clones by activating defense mechanisms,
such as induction of senescent-like arrest and apoptotic
programs, to prevent replication of defective cells (Lane, 1992;
Vogelstein et al., 2000). The critical importance of this protective
functionality is underscored by the diversity of molecular strate-
gies employed by cancer cells to subvert p53 activity, such as
deletions (Baker et al., 1989), mutations (Baker et al., 1989),
protein destruction (Honda et al., 1997; Momand et al., 1992),
or protein sequestration (Moll et al., 1995).
Restoration of p53 activity remains an important goal in the
quest for more effective cancer therapeutics (Brown et al.,
2009). Re-establishing wild-type p53 functionality in the context
of genetic deletion or mutation has been especially daunting.
However, when wild-type p53 is present, targeting its negativeSignificance
As guardian of the genome, p53 protects the cell from genetic
cells disarm p53 by a variety of mechanisms, including overex
deregulation of the p53 pathway one of the most common def
based on the p53 transactivation domain to interrogate and ove
the formation of p53-HDMXcomplexes reflects a resistanceme
for cancer cell susceptibility to HDMX inhibition. Pharmacologi
pathway and suppressed the growth of an HDM2 inhibitor-res
Canregulators holds promise to reinstate the p53 tumor suppressor
pathway (ToledoandWahl, 2006;WadeandWahl, 2009).Genetic
studies demonstrated that MDM2 and MDM4/MDMX exert
protein interaction-mediated control over p53 activity through
largely nonoverlapping mechanisms (Itahana et al., 2007;
Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant
et al., 2001). MDM2 is an E3 ubiquitin ligase that directly binds
to andmediates ubiquitylation of p53, targeting it for proteasomal
degradation (Honda et al., 1997; Tao and Levine, 1999).
In contrast, MDM4/MDMX inhibits p53 transactivation through
protein interaction-mediated sequestration (Ohtsubo et al.,
2009; Shvarts et al., 1996). Certain human cancer cells exploit
this natural regulatory axis by overexpressing HDM2 or HDMX
to suppress p53 (Danovi et al., 2004; Fakharzadeh et al., 1991;
Laurie et al., 2009;Oliner et al., 1992;Ramoset al., 2001), prompt-
ing a pharmacologic quest to target these negative regulators for
cancer therapy.
The crystal structure of the p53-HDM2 binding interface
revealed that a hydrophobic cleft on the N-terminal surface ofassault by triggering cell-cycle arrest and apoptosis. Cancer
pression of the p53 antagonists HDM2 and HDMX, making
ects in human cancer. We employed a stapled peptide helix
rcomeHDMX-mediated p53 antagonism in cancer.Whereas
chanism toHDM2 targeting, it likewise serves as a biomarker
c disruption of the p53-HDMX interaction reactivated the p53
istant tumor in vivo.
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Figure 1. Primary Sequence and HDM2/HDMX Binding Activity of
SAH-p53-8
(A) Composition of wild-type p5314–29, SAH-p53-8, and SAH-p53-8F19A
peptides.
(B) Direct binding of FITC-peptides to recombinant HDMX as measured by
fluorescence polarization.
(C and D) Competition of SAH-p53-8 and Nutlin-3 with FITC-SAH-p53-8 for
binding to HDM2 (C) and HDMX (D). mP, units of millipolarization. Data are
mean ± SEM for experiments performed in at least triplicate.
Cancer Cell
HDMX Targeting Reactivates p53 in Resistant CancerHDM2 directly engages the p53 transactivation domain, which
forms an amphipathic a helix (Kussie et al., 1996). This seminal
structural insight led to the development of a series of small
molecules and peptides that target the p53-binding pocket of
HDM2, disrupt the p53-HDM2 interaction, stabilize p53, and
thereby reduce cancer cell viability (Bernal et al., 2007; Gras-
berger et al., 2005; Koblish et al., 2006; Kritzer et al., 2004;
Shangary et al., 2008; Vassilev et al., 2004; Yin et al., 2005).
For example, Nutlin-3 is a small molecule that inhibits HDM2,
triggers cell-cycle arrest and apoptosis, and exhibits antitumor
efficacy in an osteosarcoma murine xenograft model (Vassilev
et al., 2004). Whereas select cancer cell lines readily undergo
single-agent Nutlin-3-induced apoptosis (Drakos et al., 2007;
Tabe et al., 2009), expression of HDMX, which does not bind
Nutlin-3, can prevent activation of cell death programs and
engender resistance (Hu et al., 2006; Patton et al., 2006; Wade
et al., 2006). Given the importance of HDMX in regulating p53
dynamics and its emerging role in the pathogenesis, mainte-
nance, and chemoresistance of human cancer (Danovi et al.,
2004; Laurie et al., 2006; Ramos et al., 2001; Wade et al.,
2006; Wang et al., 2007), the development of compounds to
investigate and target HDMX in cells has become a pressing
therapeutic goal (Harker et al., 2009; Hayashi et al., 2009; Hu
et al., 2007; Kallen et al., 2009; Li et al., 2008; Michel et al.,
2009; Pazgier et al., 2009; Reed et al., 2010).
We have applied a chemical strategy termed ‘‘hydrocarbon
stapling’’ that installs an all-hydrocarbon crosslink within
synthetic peptides to restore their a-helical structure, confer
protease resistance, and promote cellular uptake (Bird et al.,
2010; Schafmeister et al., 2000; Walensky et al., 2004). The
resultant ‘‘stapled peptides’’ recapitulate the biological function
of natural a-helical domains and have been deployed to interro-
gate and modulate intracellular protein interactions for mecha-
nistic analyses and potential therapeutic benefit (Gavathiotis
et al., 2008; Stewart et al., 2010; Walensky et al., 2004). Using
this approach, we previously generated Stabilized Alpha Helix
of p53 (SAH-p53) peptides modeled after the transactivation
domain of p53 and demonstrated that these compounds
targeted HDM2 in situ and reactivated the p53 pathway in
HDM2-overexpressing osteosarcoma cells (Bernal et al., 2007).
As a recent structural analysis determined that HDMX engages
the p53 transactivation a helix in a manner similar to HDM2
(Popowicz et al., 2008), we examined the HDMX targeting
capacity of our most effective HDM2 inhibitor, SAH-p53-8, and
the functional consequences of HDMX inhibition.
RESULTS
SAH-p53-8 Is a Potent HDMX Binder
SAH-p53-8 was designed based on the peptide sequence of the
p53 transactivation domain a helix (Bernal et al., 2007) (Fig-
ure 1A). We replaced natural amino acids at positions S20 and
P27 with synthetic olefinic residues, and generated the structur-
ally reinforcing hydrocarbon staple by olefin metathesis (Bird
et al., 2008). Additional residues not required for HDM2 interac-
tion were also modified to improve peptide solubility and uptake
(Bernal et al., 2007). Substitution of F19 (an essential amino acid
for HDM2 interaction; Bo¨ttger et al., 1997) with alanine yielded
a negative control for biological experiments. HDMX binding412 Cancer Cell 18, 411–422, November 16, 2010 ª2010 Elsevier Incwas examined by fluorescence polarization using full-length
HDMX and FITC-labeled derivatives of wild-type p5314–29,
SAH-p53-8, and SAH-p53-8F19A. FITC-SAH-p53-8 displayed
strong affinity for HDMX (KD = 2.3 ± 0.2 nM), surpassing that
previously reported for HDM2 (KD = 55 ± 11 nM; Bernal et al.,
2007), whereas the FITC-wild-type p5314–29 peptide and the.
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Figure 2. SAH-p53-8 Targets Both HDM2 and HDMX In Situ
SJSA-X cells were treated for 12 hr with either vehicle, FITC-SAH-p53-8
(15 mM), or FITC-SAH-p53-8F19A (15 mM). Anti-FITC immunoprecipitates
from cellular extracts were subjected to HDM2 and HDMX western analyses,
with b-actin used as a loading control. The presence of FITC-labeled peptide in
the extracts was detected by a fluorescence scan of the immunoblot.
Cancer Cell
HDMX Targeting Reactivates p53 in Resistant Cancerpoint mutant FITC-SAH-p53-8F19A showed no interaction in this
dose range (Figure 1B).
We performed competition binding assays to test the capacity
of acetyl-capped SAH-p53-8 to disrupt the high-affinity
complexes of FITC-SAH-p53-8 with HDM2 and HDMX. Both
SAH-p53-8 and the selective HDM2-inhibitor Nutlin-3 effectively
competed with FITC-SAH-p53-8 for HDM2 binding (Figure 1C).
The relatively larger interaction surface of a stapled peptide
compared to a small molecule may explain in part why SAH-
p53-8 is more effective than Nutlin-3 in this assay. Importantly,
only SAH-p53-8 was capable of dissociating the FITC-SAH-
p53-8/HDMX interaction (Figure 1D). Taken together, these
data demonstrate that SAH-p53-8 targets both HDM2 and
HDMX in vitro, and exhibits a greater than 25-fold binding prefer-
ence for HDMX over HDM2.
SAH-p53-8 Targets Both HDM2 and HDMX In Situ
We investigated the capacity of SAH-p53-8 to target intracellular
HDM2 and HDMX by conducting immunoprecipitation experi-
ments in SJSA-X cells, an HDM2-overexpressing osteosarcoma
cell line engineered to also overexpress HDMX (Wade et al.,
2008). The cells were treated with vehicle, FITC-SAH-p53-8, or
FITC-SAH-p53-8F19A for 12 hr. After cellular lysis, anti-FITC
pull-down was performed, followed by HDM2 and HDMX
western analyses. Native HDM2 andHDMX specifically coimmu-
noprecipitated with FITC-SAH-p53-8 but not with the point
mutant FITC-SAH-p53-8F19A peptide (Figure 2). A fluorescence
scan of the western blot documented the presence of FITC-
SAH-p53-8 and FITC-SAH-p53-8F19A in the cellular lysates, con-
firming that both SAH-p53 peptides efficiently penetrated intact
SJSA-X cells. These data extend our in vitro findings by demon-
strating that SAH-p53-8 can access both HDM2 and HDMX
targets within cells.
SAH-p53-8 Is Cytotoxic to Cancer Cells that
Overexpress HDM2, HDMX, or Both Proteins
We evaluated the impact of SAH-p53-8 treatment on cell viability
by treating a panel of solid tumor cells that express different
levels of HDM2 and HDMX. The cell lines included: SJSA-1, an
HDM2-overexpressing osteosarcoma; the engineered SJSA-X
derivative that overexpresses both HDM2 and HDMX; the
HDMX-overexpressing choriocarcinoma cell line JEG-3; and
the HDM2- and HDMX-expressing breast and colon cancer
cell lines MCF-7 and HCT116 (Figure 3) (Bunz et al., 1999;
Chen et al., 2007; Drukteinis et al., 2005; Kwok et al., 1994;
Wade et al., 2008; Xia et al., 2008). We examined the p53 depen-
dence of the compounds using SJSA-DD cells that express the
dominant-negative p53-DD protein (Shaulian et al., 1992;
Wade et al., 2008), HCT116 cells deficient in p53 (Bunz et al.,
1999), and A431 melanoma cells bearing the R273H p53 muta-
tion (Kwok et al., 1994). We also tested WS1 normal human
fibroblasts to evaluate relative toxicity in tumor versus nontrans-
formed cells.
Cultured cells were treated with serial dilutions of Nutlin-3,
SAH-p53-8, or the SAH-p53-8F19A point mutant control.
Whereas SJSA-1 cells were very sensitive to treatment with Nut-
lin-3, SJSA-X and JEG-3 cells showed little to no response,
consistent with the ability of Nutlin-3 to target HDM2 but not
HDMX (Figures 3A–3C). MCF-7 and HCT116 cells weremodestlyCansensitive to Nutlin-3 treatment, consistent with the coexpression
of HDM2 and HDMX in these cells (Figures 3D and 3E).
In contrast, SAH-p53-8 caused dose-dependent inhibition of
cell viability in all five cell lines, suggesting that SAH-p53-8 is
capable of reactivating the p53 pathway when cells express
elevated levels of HDM2, HDMX, or both proteins (Figures 3A–
3E). Of note, despite the relatively enhanced capacity of SAH-
p53-8 to displace the p53 transactivation helix from HDM2
compared to Nutlin-3 in vitro (Figure 1C), Nutlin-3 was more
cytotoxic than SAH-p53-8 in SJSA-1 cells (Figure 3A). This
apparent discrepancy likely derives from (1) the preferential
HDMX-binding activity of SAH-p53-8 compared to HDM2, thus
lowering the effective concentration of SAH-p53-8 available for
HDM2 targeting, and (2) the differential efficiencies of cellular
import mechanisms for stapled peptides (i.e., pinocytosis;
Bernal et al., 2007; Walensky et al., 2004) and small molecules
(i.e., diffusion). Consistent with the in vitro binding data, which
revealed a binding preference of SAH-p53-8 for HDMX over
HDM2 (Figure 1A) (Bernal et al., 2007), SJSA-X cells were more
susceptible to SAH-p53-8 than SJSA-1 cells (Figures 3A and
3B). Strikingly, the HDMX-overexpressing JEG-3 cells were
most sensitive to SAH-p53-8 but most resistant to Nutlin-3
(Figure 3C), a key finding that formed the basis for our mecha-
nistic analysis below.
Importantly, we first confirmed that SAH-p53-8 cytotoxicity is
specifically dependent on wild-type p53 protein activity and
does not significantly affect the viability of normal fibroblasts.
Genetic deletion of p53 from HCT116 cells (Bunz et al., 1999)
or overexpression of a dominant-negative form of p53 in
SJSA-1 cells (Shaulian et al., 1992; Wade et al., 2008) rendered
both cell types completely insensitive to Nutlin-3 and SAH-p53-8
(Figures 3F and 3G). The A431 melanoma cell line, which bears
an inactivating p53 point mutation, was similarly unaffected by
the treatments. We also found that SAH-p53-8, like Nutlin-3,
had no impact on the viability of normal human fibroblasts (Fig-
ure 3I). As a further measure of specificity, the mutant peptide
SAH-p53-8F19A was inactive in all cell lines tested (Figures 3A–
3I). These data further indicate that the antitumor cell activity of
SAH-p53-8 is peptide-sequence dependent and derives from
its intracellular targeting of HDM2 and HDMX.cer Cell 18, 411–422, November 16, 2010 ª2010 Elsevier Inc. 413
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Figure 3. Viability of Cancer Cells Exposed to HDM2/HDMX Inhibitors
Cancer cell lines with differential expression levels of HDM2 and HDMX (A–E), deficient or dysfunctional p53 (F–H), and a non-tumor cell control (I) were treated
with 0.3–20 mMNutlin-3, SAH-p53-8, or SAH-p53-8F19A for 24 hr. The cells were exposed to CellTiter-Glo reagent (Promega) and viability was assessed by ATP-
induced chemiluminescence. Data are mean ± SEM for experiments performed in at least triplicate.
Cancer Cell
HDMX Targeting Reactivates p53 in Resistant CancerSAH-p53-8 Blocks HDMX-Mediated Sequestration
of p53 and Reactivates the p53 Tumor Suppressor
Pathway
We performed immunoprecipitation studies in JEG-3 cells to
interrogate whether the apparent pharmacologic advantage of
SAH-p53-8 in Nutlin-3-resistant cells derives from HDMX target-
ing. After 6 hr treatment with vehicle, SAH-p53-8, or Nutlin-3,
cellular extracts were prepared and subjected to anti-HDMX
pull-down, followed by p53 western analysis. We found that
JEG-3 cells had robust levels of p53 protein, which coimmuno-
precipitated with HDMX (Figure 4A). Whereas an increase in
p53 levels was observed upon treatment with either SAH-p53-
8 or Nutlin-3 (Figure 4A), only SAH-p53-8 treatment impacted
JEG-3 cell viability (Figure 3C). We examined whether SAH-
p53-8 treatment prevents HDMX-mediated sequestration of
p53, especially when p53 levels are further boosted by HDM2
blockade. Indeed, SAH-p53-8 effectively blocked the formation
of p53-HDMX complexes (Figure 4A). In contrast, p53-HDMX
complexes were preserved, if not increased, in Nutlin-3-treated
cells. To stabilize p53 levels even further, we treated cells with
the proteasome inhibitor MG-132 and correspondingly observed
increased p53-HDMX complex, which was dose-responsively
inhibited by SAH-p53-8 treatment (Figure 4B). To confirm this
observation in a cellular context, we employed a proximity
ligation in situ assay, or P-LISA, and directly monitored p53-
HDMX complex formation and pharmacologic dissociation in414 Cancer Cell 18, 411–422, November 16, 2010 ª2010 Elsevier Inccells (So¨derberg et al., 2006) (Figures 4C–4E). U2OS osteosar-
coma cells containing a doxycycline-inducible HA-HDMX
construct (Wang et al., 2007) were treated with doxycycline in
the presence or absence of SAH-p53-8, Nutlin-3, or both. In
the presence of doxycycline alone, the HA-HDMX produced
binds to endogenous p53, leading to the formation of detectable
but low-intensity P-LISA foci (Figures 4D and 4E). The combina-
tion of doxycycline and Nutlin-3 treatment generated a robust
P-LISA signal, which represents abundant formation of p53/
HA-HDMX complexes (Figures 4D and 4E). Despite similar levels
of p53 induction in response to single-agent SAH-p53-8 or
Nutlin-3 treatment (Figure 4C), the P-LISA signal generated by
treatment with doxycycline was blocked upon cotreatment
with SAH-p53-8 (Figures 4D and 4E). Furthermore, combining
SAH-p53-8 with doxycycline/Nutlin-3 significantly reduced the
P-LISA signal generated by the doxycycline/Nutlin-3 combina-
tion alone (Figures 4D and 4E). Taken together, the immunopre-
cipitation and P-LISA data document that SAH-p53-8, but not
Nutlin-3, inhibits the formation of p53-HDMX complexes due to
its capacity to target intracellular HDMX.
To link the pharmacologic disruption of the p53-HDMX
protein complex by SAH-p53-8 with reactivation of the p53
tumor suppressor pathway, we monitored the transcriptional
activation of p53 targets by quantitative PCR (qPCR) analysis
and the induction of apoptosis using a caspase-3/7 activation
assay. JEG-3 cells were treated with vehicle, Nutlin-3 (20 mM),.
Cancer Cell
HDMX Targeting Reactivates p53 in Resistant Canceror SAH-p53-8 (20 mM) for 6 hr at 37C, followed by RNA isola-
tion, reverse transcription, and qPCR analysis of the derived
cDNA substrate using HDM2, p21, and MIC-1 primers
(Figure 5A). Whereas Nutlin-3 induced modest (1.5- to 4-fold)
upregulation of p53 transcriptional targets compared to vehicle,
SAH-p53-8 triggered significantly higher (5- to 14-fold) mRNA
levels for the same target genes. Correspondingly, SAH-p53-8
treatment caused dose-responsive activation of caspase-3/7,
whereas Nutlin-3 had little effect (Figure 5B). Thus, targeted
disruption of the p53-HDMX complex by SAH-p53-8 in Nutlin-
3-resistant JEG-3 cells coincides with upregulation of p53
transcriptional targets, caspase-3/7 activation, and reduced
tumor cell viability.
Suppression of JEG-3 Tumor Growth by Reactivation
of the p53 Pathway In Vivo
To determine whether SAH-p53-8 could modulate the p53
pathway in vivo and thereby inhibit tumor growth, we compared
the activity of vehicle, Nutlin-3, and SAH-p53-8 in a JEG-3
murine xenograft model. JEG-3 xenografts were established
by injecting 107 cells subcutaneously into the flanks of NOD-
SCID-IL2Rgnull (NSG) mice. When tumors reached an average
volume of 100 mm3 as determined by caliper measurements,
cohorts (n = 7) were treated intravenously with vehicle
(5% DMSO in dextrose 5% in water [D5W]), SAH-p53-8
(10 mg/kg), or Nutlin-3 (10 mg/kg) daily for 4 days. Whereas
the tumor growth rate was not affected by Nutlin-3 treatment,
SAH-p53-8 significantly suppressed tumor growth, achieving
and maintaining a 37%–46% reduction in tumor burden
compared to vehicle and Nutlin-3 throughout the 5 day evalua-
tion period (Figure 6A). On day 5, the tumors were excised,
flash-frozen, and RNA was extracted for qPCR analysis using
the HDM2, p21, and MIC-1 primer sets. Like the corresponding
in vitro study performed with cultured JEG-3 cells, SAH-p53-8
induced statistically significant transcriptional activation of
HDM2, p21, andMIC-1 in the tumors of treated mice (Figure 6B).
Histologic examination of SAH-p53-8-treated mice showed no
obvious toxicity of the compound to normal tissues, consistent
with the inactivity of SAH-p53-8 in cell viability assays using
cultured WS1 fibroblasts (Figure 3I). These in vivo data under-
score the pharmacologic potential of HDMX targeting to func-
tionally suppress tumor growth by reactivating the p53 pathway
in the context of HDMX-mediated p53 suppression and Nutlin-3
resistance.
Blueprint for Matching HDM2, HDMX, or Dual Inhibitors
to Susceptible Cancer Cells
Because HDMX targeting by SAH-p53-8 was most effective in
reducing tumor cell viability when basal p53 levels were naturally
elevated, we performed synergy studies in Nutlin-3-resistant
cells to test whether SAH-p53-8-mediated HDMX inhibition
could resensitize cells to Nutlin-3-mediated p53 upregulation.
In cells with high HDMX, the pool of p53 induced by Nutlin-3
treatment can be sequestered in p53-HDMX complexes,
subverting Nutlin-3 activity. We hypothesized that HDMX
blockade by SAH-p53-8 could restore Nutlin-3 activity by
preventing HDMX-mediated p53 sequestration. The breast
adenocarcinoma cell line MCF-7 overexpresses HDMX (Danovi
et al., 2004) and is only modestly sensitive to Nutlin-3 treatmentCan(Wade et al., 2008). Whereas Nutlin-3 can elevate p53 levels in
MCF-7 cells, this increase in p53 coincides with the appearance
of the inhibitory p53-HDMX complex, limiting Nutlin-3 cytotox-
icity (Figure 7A). However, by employing Nutlin-3, we pharmaco-
logically transform MCF-7 cells into a JEG-3-like state that
manifests increased abundance of p53 in complex with HDMX.
When combined, SAH-p53-8 and Nutlin-3 sensitize one another
in a dose-responsive fashion (Figures 7B and 7C), with synergy
confirmed by CalcuSyn dose-effect analysis (Chou, 2006)
(Figure 7D). The enhanced cytotoxicity observed upon cotreat-
ment with SAH-p53-8 correlates with its blockade of p53-
HDMX complex formation (Figure 7A), consistent with the added
capacity of SAH-p53-8 to target HDMX, a key source of resis-
tance in MCF-7 cells. Importantly, Nutlin-3 does not synergize
with SAH-p53-8 in JEG-3 cells (Figure 7E), because endogenous
p53 levels are already elevated. Conversely, when HDMX and
p53 expression levels are low and the cellular phenotype is
instead driven by HDM2 expression, as in SJSA-1 cells, cotreat-
ment with SAH-p53-8 provides no added benefit to Nutlin-3
(Figure 7F). However, induction of HDMX expression in this
isogenic cell line completely alters the synergy results, rendering
Nutlin-3 ineffective as a single agent, restoring susceptibility to
SAH-p53-8, and re-establishing the synergistic benefit of
combining Nutlin-3 with SAH-p53-8 treatment (Figure 7G).
These synergy analyses provide a mechanistic framework for
determining how to optimally apply HDM2- and HDMX-targeting
agents to reactivate the p53 pathway in cancer. Indeed, HDMX
targeting is maximally effective when p53 levels are naturally or
pharmacologically increased, as reflected by the presence of
detectable p53-HDMX complexes, a potentially valuable
biomarker for predicting therapeutic efficacy and monitoring
the pharmacodynamic effects of treatment.DISCUSSION
p53 lies at the crossroads of an intricate signal transduction
network that regulates cell-cycle progression, apoptosis, senes-
cence, and a host of other homeostatic functions (Brown et al.,
2009). As such, p53 levels are governed by a cascade of tran-
scriptional, posttranslational, and protein interaction-based
control systems. For example, in response to DNA damage,
the ATM kinase phosphorylates p53, reducing its binding to
HDM2 and HDMX and thereby enhancing p53 stability and
activity (Shieh et al., 1997; Siliciano et al., 1997). HDM2 and
HDMX are likewise phosphorylated, which leads to increased
ubiquitylation of both negative regulators, targeting them for
accelerated proteasomal degradation. This heightened turnover
of HDM2 and HDMX also contributes to p53 stabilization and
activation (Meulmeester et al., 2005; Pan and Chen, 2003; Stom-
mel and Wahl, 2004). Dissociation of the deubiquitylating
enzyme HAUSP participates in the switch of HDM2-mediated
ubiquitylation activity from p53 to itself and HDMX (Meulmeester
et al., 2005). These responses are ultimately tempered by the
transcriptional autoinhibitory feedback loop of p53, which
restores HDM2 levels and downregulates p53 activity. Whereas
the relative protein levels and regulatory mechanisms of p53,
HDM2, and HDMX vary among cells, overexpression of HDM2
and HDMX has emerged as a formidable barrier to reactivationcer Cell 18, 411–422, November 16, 2010 ª2010 Elsevier Inc. 415
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Figure 5. Reactivation of p53-Dependent Transcription and
Apoptosis by SAH-p53-8
(A) JEG-3 cells were treated with vehicle, SAH-p53-8 (20 mM), or Nutlin-3
(20 mM), and transcriptional upregulation of HDM2, p21, and MIC-1 was eval-
uated by qPCR analysis.
(B) JEG-3 cells were treatedwith vehicle, 0.3–10 mMSAH-p53-8, or Nutlin-3 for
12 hr, followed by exposure to Caspase-Glo 3/7 reagent (Promega). Caspase-
3/7 activation was assessed by monitoring the cleavage of proluminescent
caspase-3/7 substrate. Data are mean ± SEM for experiments performed in
at least triplicate. RLU, relative luminescence units.
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Figure 6. SAH-p53-8 Overcomes HDMX-Mediated p53 Suppression
and Blocks Tumor Growth In Vivo
(A) Cohorts (n = 7) of JEG-3 xenograft mice were treated with vehicle (5%
DMSO in D5W) or 10 mg/kg of SAH-p53-8 or Nutlin-3 by intravenous injection
daily for 4 days and tumor volume was monitored by caliper measurement on
days 1, 3, 4, and 5. Data are mean ± SD (day 3: SAH/Veh, p = 0.032; SAH/Nut,
p = 0.032; Nut/Veh, p = 0.94; day 4: SAH/Veh, p = 0.008; SAH/Nut, p = 0.026;
Nut/Veh, p = 0.88; day 5: SAH/Veh, p = 0.017; SAH/Nut, p = 0.037; Nut/Veh,
p = 0.46).
(B) RNA was prepared from the excised JEG-3 tumors and qPCR analysis was
performed tomeasure levels of the p53 transcriptional targetsHDM2, p21, and
MIC-1. Data are mean ± SEM.
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HDMX Targeting Reactivates p53 in Resistant Cancerof the p53 tumor suppressor pathway in cancer (Marine et al.,
2007; Toledo and Wahl, 2006).
Restoring p53 activity by targeting its negative regulators is
a promising strategy for treating cancers that retain wild-type
p53. We previously developed SAH-p53-8 as an HDM2-target-
ing agent, but now find that it has a 25-fold greater binding pref-
erence for HDMX. SAH-p53-8 targets HDMX in cells, blocks
formation of the p53-HDMX interaction, and thereby restores
the p53 pathway, as evidenced by transcriptional upregulation
of p53 targets and reduction of tumor cell viability. The on-target
specificity of SAH-p53-8 activity is highlighted by the explicit
p53 dependence of its effects and the complete abrogation of
functional activity by single-point mutagenesis of a critical
residue at the a helix binding interface. Importantly, intravenous
administration of SAH-p53-8 to mice bearing an HDMX-ex-Figure 4. SAH-p53-8 Blocks the Formation of p53-HDMX Complexes
(A) JEG-3 choriocarcinoma cells were exposed to vehicle, 20 mM SAH-p53-8, or
were subjected to SDS-PAGE and analyzed by western blotting for p53, HDMX,
(B) JEG-3 cells were treated with 0–20 mM SAH-p53-8 in the presence of 10 mM
analyzed by western blotting for p53, HDMX, and HAUSP.
(C) Doxycycline-inducible U2OS cells were treated with or without doxycycline in
HA-HDMX and p53 was detected and quantitated by immunofluorescence. The
(D) Cultured U2OS cells were treated with or without doxycycline in the presence
represent 10 mm.
(E) Quantitation of p53-HDMX complexes as detected by P-LISA. Data are mean
Canpressing and Nutlin-3-resistant cancer also triggered upregula-
tion of p53 transcriptional targets and suppressed tumor growth.
In addition to validating an intracellular HDMX inhibitor using
in vitro and in vivo analyses, what has also emerged from this
study is a mechanism-based framework for (1) determining
which cancer cells will be susceptible to single-agent HDM2 or
HDMX inhibition and (2) overcoming p53 suppression in
a resistant cell through synergistic HDM2 and HDMX targeting.
Whereas sensitivity to single-agent HDM2 inhibition is predom-
inantly determined by the presence or absence of HDMX
(Figures 8A and 8B), susceptibility to HDMX targeting is
dependent upon the cellular level of p53 (Figures 8C and 8D).
Our analysis of SAH-p53-8 activity in HDMX-expressing,20 mM Nutlin-3 for 6 hr. Cellular extracts and anti-HDMX immunoprecipitates
and HAUSP.
MG-132 for 6 hr. Cellular extracts and anti-HDMX immunoprecipitates were
the presence of Nutlin-3 (10 mM), SAH-p53-8 (10 mM), or both, and induction of
scale bars represent 10 mm.
of Nutlin-3, SAH-p53-8, or both and then processed for P-LISA. The scale bars
± SD. *p = 0.0003, **p = 0.0001, unpaired t test with Welch’s correction.
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Figure 7. Pharmacologic Induction of p53-HDMX
Complexes Sensitizes Nutlin-3-Resistant Cancer Cells
to HDMX Inhibition
(A) MCF-7 breast adenocarcinoma cells were exposed to
vehicle, Nutlin-3 (20 mM), or Nutlin-3 in combination with 5 or
20 mM SAH-p53-8 in the presence of 10 mM MG-132 for 6 hr.
Cellular extracts and anti-HDMX immunoprecipitates were
subjected to SDS-PAGE and analyzed by western blotting
for p53, HDMX, and HAUSP.
(B and C) For synergy studies, MCF-7 cells were treated with
5–20 mM SAH-p53-8 with or without 20 mM Nutlin-3 (B) or 5–
20 mM Nutlin-3 with or without 20 mM SAH-p53-8 (C), and
cell viability was measured at 24 hr by CellTiter-Glo assay.
Data are mean ± SEM for experiments performed in at least
triplicate.
(D–G) Dose-effect synergy analyses of MCF-7 (D), JEG-3 (E),
SJSA-1 (F), and SJSA-X (G) cells treated with 0.5–20 mM
SAH-p53-8, Nutlin-3, or an equimolar combination.
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HDMX Targeting Reactivates p53 in Resistant CancerNutlin-3-resistant cells revealed that a maximal response was
achieved when baseline p53 levels were sufficiently elevated
to detect native p53-HDMX complexes, such as in JEG-3 cells.
The presence of these complexes indicates that a reservoir of
p53 can be promptly released by pharmacologic disruption of
the p53-HDMX interaction. Thus, cancers that sequester p53
via HDMX overexpression may be particularly sensitive to
SAH-p53-8 or other HDMX-specific antagonists in develop-
ment. When cellular levels of HDMX are high, HDM2 antagonists
are less effective and when p53 levels are low, targeting HDMX418 Cancer Cell 18, 411–422, November 16, 2010 ª2010 Elsevier Inc.is essentially inconsequential. In this resistant
context, pharmacologic induction of p53 by
HDM2 antagonists combined with HDMX blockade
to inhibit p53 sequestration optimally reactivates
the p53 pathway (Figure 8E). Thus, we find that tar-
geting HDMX can overcome HDMX-mediated p53
suppression and resistance to selective HDM2
inhibition, whereas dual targeting of HDM2 and
HDMX can maximize therapeutic reactivation of
the p53 tumor suppressor pathway in cancers
that retain wild-type p53 but maintain pathologi-
cally low levels of p53 expression. Importantly,
monitoring cellular levels of p53-HDMX complex
can both predict cancer cell susceptibility to
single-agent HDMX inhibition and determine the
efficacy of HDM2-mediated p53 upregulation,
which forms the basis for enhancing the thera-
peutic impact of dual HDM2/HDMX targeting.
EXPERIMENTAL PROCEDURES
Peptide Synthesis
Peptide synthesis, olefin metathesis, FITC derivatization,
reverse-phase HPLC purification, and amino acid analysis
were performed as previously reported (Bernal et al., 2007;
Bird et al., 2008).
Fluorescence Polarization Binding Assays
Fluorescence polarization assays were performed as previ-
ously described (Bernal et al., 2007; Pitter et al., 2008). Briefly,
to determine dissociation constants for peptide-protein inter-
actions, fluoresceinated peptides (25 nM) were incubatedwith full-length HDMX or HDM217–125 (25 pM–100 nM), and fluorescence polar-
ization was measured at equilibrium on a SpectraMax M5 microplate reader
(Molecular Devices). For competition assays, FITC-peptide (25 nM) was
combined with a serial dilution of Nutlin-3 (EMD Chemicals) or unlabeled
SAH-p53-8 followed by addition of HDM2 or HDMX protein (100 nM). IC50
values for FITC-peptide displacement were calculated by nonlinear regression
analysis using Prism software (GraphPad). Recombinant HDM2 was gener-
ated as previously reported (Bernal et al., 2007). To generate recombinant
HDMX, Escherichia coli BL21 (DE3) pLysS containing the plasmid encoding
full-length HDMX with N-terminal thioredoxin, S, and hexahistidine tags, and
an engineered TEV protease cleavage site (pET32-LIC vector; Novagen)
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Figure 8. Molecular Determinants of Cancer Cell Susceptibility to
HDM2, HDMX, and Dual Inhibition
In the context of HDM2-driven p53 suppression, HDM2 inhibition triggers
a surge in p53 levels and induces cancer cell death (A). However, if HDMX is
present, p53 can become sequestered in p53-HDMX complexes, limiting the
cellular response to HDM2 inhibition (B). When p53-HDMX complex levels
are elevated, HDMX inhibition reactivates the p53 pathway and induces cell
death (C). However, if cellular levels of p53 are low, targeting HDMX has little
to no effect on cell viability (D). When p53 levels are suppressed by HDM2, and
HDMX is also expressed, maximal reactivation of the p53 pathway is achieved
by combined blockade of HDM2 and HDMX, which elevates p53 levels and
blocks formation of inhibitory p53-HDMX complexes, respectively (E). Thus,
cancer cell susceptibility to pharmacologic inhibition of HDM2, HDMX, or
both targets is determined by the respective levels and interactions of p53,
HDM2, and HDMX.
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HDMX Targeting Reactivates p53 in Resistant Cancerwere cultured in ampicillin- and chloramphenicol-containing Luria-Bertani
broth and induced with 0.1 mM isopropyl b-D-thiogalactoside. The cells
were harvested after 6 hr by centrifugation for 20 min at 3,200 rpm, resus-
pended in buffer A (20 mM Tris [pH 8.0], 0.5 M NaCl), and lysed by sonication.
Cellular debris was pelleted by centrifugation for 30min at 15,000 rpm, and the
supernatant was incubated with Ni-NTA agarose (QIAGEN) for 2 hr. The resin
was washed with buffer A and eluted with a gradient of imidazole ranging from
5 to 500 mM. The fractions containing the eluted protein were concentrated
and treated overnight with recombinant TEV S219V protease (Kapust et al.,
2001) at 4C. The reaction was concentrated to 2ml and purified by size-exclu-
sion chromatography using a G200 column. Purity of the protein was assessed
by SDS-PAGE and its identity was confirmed by MALDI-TOF mass
spectrometry.
Cell Viability Assays
Cultured cells were maintained in the indicated media supplemented with fetal
calf serum and penicillin/streptomycin: SJSA-1, SJSA-X, SJSA-DD, A431
(DMEM); JEG-3, MCF-7, WS1 (EMEM); HCT116 (McCoy’s 5A). For viability
analysis, cells (1 3 104) were seeded in 96-well plates overnight, washed in
PBS, and then incubated with peptides, Nutlin-3 (EMD Chemicals), or both
in OPTI-MEM (Invitrogen) at the indicated doses for 24 hr. Cell viability was
assayed by addition of CellTiter-Glo chemiluminescence reagent accordingCanto the manufacturer’s protocol (Promega) and luminescence was measured
using a SpectraMax M5 microplate reader (Molecular Devices). Data are
normalized to vehicle-treated controls. Synergy between SAH-p53-8 and
Nutlin-3 was calculated using the CalcuSyn software package (Chou, 2006)
(Biosoft). Viability assays were performed in at least triplicate.
Quantitative RT-PCR
JEG-3 cells (7.53 106) were seeded in 6-well plates and treated with vehicle or
20 mMSAH-p53-8 or Nutlin-3 (EMD Chemicals) and incubated for 6 hr at 37C.
RNA samples were prepared using the RNeasy Mini kit (QIAGEN). Total RNA
was reverse transcribed to cDNA using Superscript III reverse transcriptase
(Invitrogen). The derived cDNA was employed as the substrate to measure
relative transcript levels by qRT-PCR on a PRISM 7700 system using SYBR
Green PCR Master Mix (Applied Biosystems). Primers specific for HDM2,
p21, MIC-1, and the UBB control were employed. Triplicate reactions were
prepared in 96-well optical PCR plates. Threshold-cycle (Ct) values were
automatically calculated for each replicate and used to determine the relative
expression of the gene of interest relative to UBB for both treated and
untreated samples by the 2DDCt method (Livak and Schmittgen, 2001).
Caspase-3/7 Activation Assay
JEG-3 cells (13 104) were seeded in 96-well plates overnight, washed in PBS,
and then incubated with the indicated doses of SAH-p53-8 or Nutlin-3 (EMD
Chemicals) in OPTI-MEM (Invitrogen) for 12 hr. Caspase-3/7 activity was as-
sayed by addition of Caspase-Glo 3/7 chemiluminescence reagent according
to the manufacturer’s protocol (Promega) and luminescence was measured
using a SpectraMax M5 microplate reader (Molecular Devices).
Coimmunoprecipitation Analysis
Anti-FITC pull-down experiments were performed as previously described
(Pitter et al., 2008; Walensky et al., 2006). Briefly, cells (1.53 106) were treated
with FITC-SAH-p53 peptides (15 mM) and lysed in buffer B (0.1% Triton X-100,
50 mM Tris [pH 7.4], 150 mM NaCl, 1 mM PMSF, EDTA-free protease inhibitor
tablet [Roche], and 20 U/ml benzonase nuclease [EMD Chemicals]). Proteins
were coimmunoprecipitated with goat-anti-FITC antibody (Abcam) and
western analysis of electrophoresed proteins was performed using mouse
anti-HDM2 (IF2; EMD Chemicals), rabbit anti-HDMX (BL1258; Bethyl Labora-
tories), and b-actin (Sigma) antibodies. Fluorescence imaging of the blot was
performed using a Typhoon 8600 Imaging System (Molecular Dynamics).
For HDMX immunoprecipitation experiments, cells (1.5 3 106) were treated
with either SAH-p53-8 or Nutlin-3 (EMD Chemicals) at the indicated doses in
0.5 ml OPTI-MEM (Invitrogen) with or without 10 mM MG-132 for 6 hr. After
washing with PBS (23 1ml), the cells were lysed in buffer B. HDMXwas immu-
noprecipitated with anti-HDMX antibody (BL1258; Bethyl Laboratories) and
western analysis of electrophoresed protein was conducted using p53
(DO-1; EMD Chemicals or FL-393; Santa Cruz Biotechnology), HDMX
(MDMX-82; Abcam), and HAUSP (anti-USP7; Bethyl Laboratories) antibodies,
and Western Lightning chemiluminescence reagent (PerkinElmer).
P-LISA and Immunofluorescence
U2OS cells expressing a doxycycline-inducible HA-HDMX construct (Wang
et al., 2007) were seeded onto coverslips and treated with doxycyline for
24 hr. SAH-p53-8 (10 mM), enantiomeric Nutlin-3 (10 mM) (Roche), or both
compounds were added for the final 8 hr of treatment. The cells were fixed
in 3.7% paraformaldehyde, washed in PBS, and permeabilized in 0.2% Triton
X-100 for 5 min. Coverslips were then blocked in 10% normal goat serum
(NGS) in PBS for 2 hr. For P-LISA, primary antibodies HA.11 (BabCo; 1:500)
and FL393 (Santa Cruz Biotechnology; 1:1000) were diluted in PBS/EDTA/
0.2% Triton X-100/2% NGS and incubated at 4C overnight. Following
washes with TBS/0.05% Tween-20, a proximity ligation in situ assay
(P-LISA) was performed according to the manufacturer’s protocol (Detection
Kit 613; OLink Bioscience) with the following exception: goat anti-rabbit
(minus) and anti-mouse (plus) P-LISA probes were diluted in NGS at 1:10
instead of 1:5. Coverslips were mounted on microscope slides and images
were acquired using OpenLab software (Improvision) and a Zeiss Axioplan 2
microscope. Nuclear foci (at least 100 cells per treatment) were quantified
using Blobfinder software (Centre for Image Analysis, Uppsala University,
Sweden). All exposure times and intensity thresholds were set based oncer Cell 18, 411–422, November 16, 2010 ª2010 Elsevier Inc. 419
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HDMX Targeting Reactivates p53 in Resistant Cancerdoxycycline/Nutlin-3 cotreatment and kept constant for each treatment. The
statistical significance of the observed differences in foci number among
the treatment conditions was determined using the unpaired t test with
Welch’s correction. For standard immunofluorescence imaging of p53 and
HA-HDMX, the antibodies indicated above were again employed, but
following the PBS washes the slides were incubated (1 hr, room temperature)
with goat anti-rabbit AF568 (1:1000) and goat anti-mouse AF488 (1:500) (Invi-
trogen/Molecular Probes) antibodies containing 1 mg/ml Hoechst. Density sli-
ces from each Hoechst image were generated in OpenLab and used as masks
to quantify the nuclear intensity of both p53 and HA-HDMX. Total intensity was
defined as average pixel intensity 3 nuclear area, and was corrected for
nuclear size differences. Graphical representation and statistical analyses
were performed using Microsoft Excel and Prism software (GraphPad).
JEG-3 Xenograft Study
JEG-3 xenografts were established by injecting 107 cells subcutaneously into
the flanks of NOD-SCID-IL2Rgnull (NSG) mice (Jackson Labs). When tumors
reached an average volume of 100 mm3, cohorts (n = 7) were treated with
vehicle (5% DMSO in D5W), SAH-p53-8 (10 mg/kg), or Nutlin-3 (10 mg/kg)
(EMD Chemicals) once daily for 4 days by intravenous injection. Tumor size
was measured with calipers on days 1, 3, 4, and 5. On day 5, the mice were
euthanized, tumors were excised, and a portion of each tumor was flash-
frozen and subjected to RNA isolation for qRT-PCR analysis, as described
above. The remainder of each animal was fixed in Bouin’s fixative and
submitted to the Dana-Farber/Harvard Cancer Center Rodent Histopathology
Core for complete necropsy. Animal experiments were approved by and per-
formed in accordance with the guidelines and regulations set forth by the Insti-
tutional Animal Care and Use Committee of the Dana-Farber Cancer Institute.
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